Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

5results about How to "Improve induction ability" patented technology

Vanadium-doped mesoporous bioactive glass powder for treating diabetic wounds and preparation method of vanadium-doped mesoporous bioactive glass powder

PendingCN121929898AEffectively maintain simulation activityHigh biosecurityPlastersGlass shaping apparatusBioactive glassPhysical chemistry
The invention relates to the technical field of biological material manufacturing, in particular to vanadium-doped mesoporous bioactive glass powder for treating diabetic wounds and a preparation method of the vanadium-doped mesoporous bioactive glass powder. Adding an ammonia solution into the template agent solution to obtain a mixed solution; adding a silicon source, a phosphorus source, a calcium source and a vanadium source into the mixed solution in batches according to a preset interval time under a continuous stirring condition, continuously stirring and reacting for 5.5-24 hours, and centrifuging and collecting a precipitation product; and washing, roasting and grinding the obtained precipitation product to obtain the vanadium-doped mesoporous bioactive glass powder for treating diabetic wounds.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV

A chimeric polypeptide, related biomaterials and their application in induced cardiomyocytes

ActiveCN121591917BAmazing transcriptional activityImprove induction efficiencyAntibody mimetics/scaffoldsGenetically modified cellsGATA6Mef2
This invention belongs to the field of biomedicine and regenerative medicine technology. It discloses a chimeric polypeptide, related biomaterials, and their application in inducing cardiomyocytes. The chimeric polypeptide is obtained through family homologous domain substitution and is selected from the following groups: (1) a MEF2 chimeric polypeptide with MEF2C protein as the backbone, wherein the N-terminal and C-terminal transcriptional activation domains are replaced by homologous regions of MEF2B and MEF2D, respectively; (2) a GATA chimeric polypeptide with GATA4 protein as the backbone, wherein the N-terminal transcriptional activation domain is replaced by homologous regions of GATA1 and GATA6. This invention also provides the nucleic acid encoding the polypeptide, the construct, and a method for efficiently inducing fibroblast reprogramming into cardiomyocytes under in vitro conditions. When the chimeric polypeptide of this invention is used alone or in combination, the induced cells exhibit calcium ion oscillations earlier and have higher maturity.
Owner:GUANGZHOU MEDICAL UNIV

Application of Dendrobium nobile in the preparation of breast cancer treatment drugs and breast cancer treatment drugs

PendingCN122075453AInhibition of activityInhibition of clonogenicityEther/acetal active ingredientsSexual disorderWestern blotPharmaceutical drug
This invention relates to the field of breast cancer therapeutics, providing a novel application of *Dendrobium nobile*, specifically the application of dendrobine in the preparation of breast cancer therapeutics. This invention verifies that dendrobine can significantly inhibit breast cancer cell viability. The inhibitory effect of dendrobine on the migration and proliferation of T47D breast cancer cells and its ability to induce cell death increases with increasing dosage. Simultaneously, cloning experiments also show that dendrobine significantly inhibits the colony-forming ability of breast cancer cells. ROS and JC-1 experiments also show that dendrobine induces mitochondrial dysfunction and increases ROS levels. Western blot experiments show that under dendrobine treatment, the expression levels of ferroptosis markers GPX4 and Nrf2 are significantly reduced. Dendrobine can promote ferroptosis in breast cancer cells and inhibit their cell viability by inducing mitochondrial dysfunction, and it holds promise as a breast cancer therapeutic drug specifically targeting ferroptosis.
Owner:SOUTHWEST MEDICAL UNIV

Efficient adhesion type insect trapper

The utility model discloses an efficient adhesion type insect trapper, and relates to the technical field of insect trapping, the efficient adhesion type insect trapper comprises a supporting plate, four photovoltaic power generation devices are installed on the periphery of the top of the supporting plate, four insertion grooves are formed in the periphery of the interior of the supporting plate, and the photovoltaic power generation devices are inserted into the insertion grooves. Two magnetic suction plates are installed on the two sides of the top of the insertion groove. An adhesion assembly is slidably connected to the interior of the insertion groove and comprises an insertion plate, the insertion plate is slidably connected to the interior of the insertion groove, an iron plate is installed at the top of the insertion plate, a grip is installed at the top of the iron plate, and a connecting plate is installed at the bottom of the insertion plate; and two pieces of second adhesive paper are mounted on the two sides of the connecting plate. According to the insect catching device, the adhesion assembly and the supporting assembly are used in cooperation, so that the insect catching effect is improved through the arrangement of the first adhesive paper and the second adhesive paper, and the first adhesive paper and the second adhesive paper can be conveniently and rapidly replaced.
Owner:SHENZHEN BAILEFU ELECTRONIC TECH CO LTD

Recombinant protein VP8: CTB for inducing long-acting rotavirus neutralizing antibody and application thereof

The invention discloses a recombinant protein VP8: CTB for inducing a long-acting rotavirus neutralizing antibody and application of the recombinant protein VP8: CTB. According to the present invention, the soluble expression of the CTB-Spycater003 carrier protein and the VP8-Spytag003 protein is achieved, and the rotavirus recombinant subunit vaccine is assembled through the in vitro coupling; the recombinant subunit vaccine has intact antigenicity and immunogenicity, and can induce mice to generate long-acting and high-titer IgG binding antibodies and broad-spectrum neutralizing antibodies.
Owner:SHANGHAI INSTITUTE OF INFECTIOUS DISEASE & BIOSECURITY